Afeyan Noubar's Form 4 filing
Sana Biotechnology, Inc.SANA · filed May 26, 2023
- Accession no.
- 0000899243-23-013992
- Filed
- May 26, 2023, 8:00 PM ET
- Trade date
- May 24-26, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions. Open-market sales total $3.53M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Afeyan NoubarCIK 0001222012 | 10% Owner |
| Flagship Ventures Fund V, L.P.CIK 0001627639 | 10% Owner |
| Flagship Ventures Fund V General Partner LLCCIK 0001724575 | 10% Owner |
| Flagship V VentureLabs Rx Fund, L.P.CIK 0001724939 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 24, 2023 | Common Stock | SSaleDisposed | −308,290 | $6.57F1 | −$2,023,985.51 | 11,276,909 | Indirect | |
| May 24, 2023 | Common Stock | SSaleDisposed | −39,580 | $6.57F1 | −$259,850.62 | 1,447,791 | Indirect | |
| May 25, 2023 | Common Stock | SSaleDisposed | −102,245 | $6.35F4 | −$649,480.69 | 11,174,664 | Indirect | |
| May 25, 2023 | Common Stock | SSaleDisposed | −13,127 | $6.35F4 | −$83,385.33 | 1,434,664 | Indirect | |
| May 26, 2023 | Common Stock | SSaleDisposed | −72,670 | $6.23F5 | −$452,479.76 | 11,101,994 | Indirect | |
| May 26, 2023 | Common Stock | SSaleDisposed | −9,330 | $6.23F5 | −$58,093.25 | 1,425,334 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.50 to $6.99, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 2 transactions in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.56, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 2 transactions in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.08 to $6.43, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 2 transactions in Table I.